Results 71 to 80 of about 5,337 (191)
Aducanumab: una mirada dos años después de su aprobación [PDF]
Alzheimer’s disease is the leading cause of dementia worldwide and a critical public health problem. While deaths from cardiovascular diseases have decreased, those attributed to Alzheimer’s disease have increased in recent years with no curative ...
Astrid Torres +5 more
core +1 more source
Aducanumab: the high costs of false hope
, 2023 As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expert consensus of medical specialists in judging the thousands of new medical advancements made each year.
Kalle Amolins (16849723)
core +3 more sources
Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review
Brain and Behavior, Volume 16, Issue 9, September 2026.ABSTRACT Purpose: Cognitive impairment is a growing global health concern associated with aging, neurodegenerative diseases, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, provide limited and variable benefits.
Hafsa Ali +4 more
wiley +1 more source
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease [PDF]
, 2016 IntroductionAducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD).MethodsThis randomized, double-blind, placebo-controlled ...
Ferrero, James +13 more
core +1 more source
Journal of Alzheimer's Disease Reports, 2022 Despite controversy about the efficacy and safety of aducanumab, the FDA’s fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have ...
Sanjana P. Padala, Brandon C. Yarns
doaj +1 more source
Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers
Protein Science, Volume 35, Issue 9, September 2026.Abstract Alzheimer's disease affects tens of millions of people worldwide and is associated with the self‐assembly of the Aβ42 peptide into amyloid aggregates. Among the species formed during this process, soluble oligomeric intermediates are the most closely linked to neurotoxicity and are therefore an attractive target for both therapeutic and ...
Magdalena Nowinska +3 more
wiley +1 more source
Unveiling Aducanumab's safety profile: A comprehensive pharmacovigilance analysis.
PLoS ONEBackgroundAducanumab, a monoclonal antibody targeting amyloid-beta plaques, has been introduced as a pivotal therapeutic agent for Alzheimer's disease (AD).
Huanhuan Ji, Zongren Zhao, Chuanwei Zhao
doaj +1 more source
Aging Cell, Volume 25, Issue 9, September 2026.The identification of the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) challenges the century‐old “immune‐privileged” dogma of the central nervous system (CNS), establishing a critical mechanistic link between impaired waste clearance (Aβ/tau) and the pathogenesis of Alzheimer's disease (AD).
Bingbing Song +10 more
wiley +1 more source
SAGE Open Medical Case Reports, 2023 A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis.
Linda L Restifo, Robert P Erickson
doaj +1 more source
Psychiatry and Clinical Neurosciences, Volume 80, Issue 9, Page 740-747, September 2026.Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Aran Tajika +5 more
wiley +1 more source